公开(公告)号：EP3279313B1

公开(公告)日：2020-11-25

申请号：EP17168855.9

申请日：2010-09-28

申请人： GlaxoSmithKline Biologicals S.A.

发明人： GERKE, Christiane ,  BERLANDA SCORZA, Francesco ,  SAUL, Allan ,  MAGGIORE, Luana

IPC分类号： C12N9/12 ,  C07K14/25 ,  C12N1/20 ,  C12N1/21 ,  A61K35/74 ,  A61K39/02 ,  A61K39/00 ,  A61K35/12 ,  A61P1/00 ,  A61P1/04 ,  A61P1/12 ,  A61P1/14 ,  A61P31/04 ,  A61P37/04 ,  C12N9/10

公开(公告)号：EP3551645A1

公开(公告)日：2019-10-16

申请号：EP17822863.1

申请日：2017-12-07

申请人： Molecular Templates, Inc.

发明人： POMA, Eric ,  WILLERT, Erin

IPC分类号： C07K14/25 ,  A61K38/04

公开(公告)号：EP3279313A3

公开(公告)日：2018-03-21

申请号：EP17168855.9

申请日：2010-09-28

申请人： GlaxoSmithKline Biologicals S.A.

发明人： GERKE, Christiane ,  BERLANDA SCORZA, Francesco ,  SAUL, Allan ,  MAGGIORE, Luana

IPC分类号： C12N1/20 ,  C12N1/21 ,  C07K14/25 ,  A61K35/74 ,  A61K39/02 ,  C12N9/12 ,  A61K39/00 ,  A61K35/12

CPC分类号： C12N1/20 ,  A61K39/00 ,  A61K2035/122 ,  C07K14/25 ,  Y02A50/476

摘要： Hyperblebbing Shigella strains are generated by disrupting one or more components of the Tol-Pal system. The blebs from these strains are useful immunogens for vaccination. The individual proteins found in these blebs can also be used as immunogens.

公开(公告)号：EP2657251B1

公开(公告)日：2018-03-21

申请号：EP13176694.1

申请日：2005-05-24

申请人： The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services

发明人： Xu, DeQi ,  Kopecko, Dennis, J.

IPC分类号： C07K14/25 ,  A61K39/112 ,  C12N15/52

CPC分类号： A61K39/0283 ,  A61K48/00 ,  A61K2039/522 ,  A61K2039/523 ,  C07K14/25 ,  C12N15/52 ,  Y02A50/484

摘要： The present invention relates to Salmonella typhi Ty21a a comprising core-linked Shigella dysenteriae type 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2; b) DNA encoding S. dysenteriae serotype 1 biosynthesis polypeptides encoded by any one of SEQ ID NOs: 1 and 2; c) DNA encoding variants of the polypeptide encoded by the DNA of (a) or (b), wherein the variants comprise O antigen biosynthesis polypeptide analogs, wherein one or more of the specified amino acids is deleted or replaced, or wherein one or more non-specified amino acids are added without loss of biosynthesis of Shigella dysenteriae serotype 1 O antigen or protective immunological activity of the O antigen biosynthesis gene product; and d) nucleic acid molecules encoding gene products that share at least about 90% sequence identity with the polypeptide encoded by the nucleic acid molecule of SEQ ID NO: 1 or 2.

公开(公告)号：EP3075388A1

公开(公告)日：2016-10-05

申请号：EP14866703.3

申请日：2014-11-25

申请人： Idemitsu Kosan Co., Ltd ,  National Center for Global Health and Medicine

发明人： SAWADA, Kazutoshi ,  MATSUI, Takeshi ,  TAKITA, Eiji ,  HAMABATA, Takashi ,  SATO, Toshio

IPC分类号： A61K39/00 ,  A23K10/40 ,  A23K50/00 ,  A61K38/00 ,  A61K39/108 ,  A61K39/112 ,  A61P1/12 ,  A61P7/10 ,  A61P31/04 ,  A61P37/04 ,  C07K14/245 ,  C07K14/25 ,  C12N15/09

CPC分类号： A61K39/0283 ,  A23K20/00 ,  A23K50/30 ,  A61K38/164 ,  A61K39/0258 ,  A61K2039/542 ,  A61K2039/552 ,  C07K14/245 ,  C07K14/25 ,  C07K2319/00 ,  Y02A50/474

摘要： The present invention provides an agent for controlling colibacillosis including a fusion protein comprising a subunit of Shiga toxin and a subunit of Escherichia coli heat-labile toxin.

摘要翻译： 本发明提供了用于控制大肠杆菌病的药剂，其包括含有志贺毒素亚基和大肠杆菌不耐热毒素亚基的融合蛋白。

公开(公告)号：EP2097529A1

公开(公告)日：2009-09-09

申请号：EP07855560.4

申请日：2007-12-17

申请人： Osprey Pharmaceuticals USA, Inc.

发明人： SU, Hongsheng ,  COGGINS, Philip, J. ,  MCINTOSH, Laura, M.

IPC分类号： C12N15/62 ,  A61K47/48 ,  A61P11/00 ,  A61P29/00 ,  A61P37/06 ,  C07K14/245 ,  C07K14/25 ,  C07K14/475 ,  C07K14/52 ,  C07K16/00 ,  C07K19/00 ,  C12N1/21 ,  C12N15/13 ,  C12N15/18 ,  C12N15/19 ,  C12N15/56 ,  C12N15/63 ,  C12N9/24 ,  C12P21/02 ,  C12Q1/00 ,  C12Q1/68

CPC分类号： C07K16/1203 ,  A61K47/6415 ,  C07K14/25 ,  C07K2319/01 ,  C07K2319/55 ,  C12N15/01 ,  C12N15/1034 ,  G01N2333/25 ,  G01N2333/415

摘要： Methods for selecting and identifying modified toxins and conjugates thereof are provided. The methods are select for toxins that exhibit reduced toxicity to the host cell in which they are expressed. Methods of increasing production of toxins, such as the modified toxins, or conjugates thereof, also are provided. In particular, in the methods the toxins, or conjugates thereof, are produced in the presence of an inhibitor molecule. Also provided, are modified toxins and conjugates thereof. Such conjugates can be used in the treatment of various disease or disorders associated with proliferation, migration, and physiological activity of cells involved in immune or inflammatory responses.

公开(公告)号：EP1979488A2

公开(公告)日：2008-10-15

申请号：EP07769138.4

申请日：2007-01-09

申请人： The Regents of the University of California Office of Technology Transfer

发明人： KORNBLUTH, Richard, Syd ,  STONE, Geoffrey, William

IPC分类号： C12P21/02 ,  C07H21/04 ,  C07K14/25 ,  C12N1/21

CPC分类号： A61K39/21 ,  A61K38/191 ,  A61K39/12 ,  A61K2039/5152 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55561 ,  C12N2740/16134 ,  C12N2740/16234 ,  A61K2300/00

摘要： This invention discloses immunostimulatory combinations of Tumor Necrosis Factor Receptor Superfamily (TNFRSF) agonists, Toll-Like Receptor (TLR) agonists, "domain present in NA IP, C IITA, H ET-E, T P-1(NACHT)- L eucine R ich R epeat (LRR)" or "NLR" agonists, RIG-I-Like Helicase or "RLH" agonists, purinergic receptor agonists and cytokine/chemokine receptor agonists, together with delivery methods. The combinations, when used alone at the site of pathology, provide immunostimulation that induces host humoral and cellular immunologic responses to eliminate pathogens or neoplasms. Alternatively, when the combinations are used with a defined antigens, these combinations can induce focused humoral and cellular immunologic responses useful as prophylactic and/or ameliorative therapeutic modalities for infections and the treatment of neoplastic disorders.

公开(公告)号：EP1756149A1

公开(公告)日：2007-02-28

申请号：EP05754091.6

申请日：2005-05-24

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： KOPECKO, Dennis, J. ,  XU, DeQi

IPC分类号： C07K14/25 ,  A61K39/112

CPC分类号： A61K39/0283 ,  A61K48/00 ,  A61K2039/522 ,  A61K2039/523 ,  C07K14/25 ,  C12N15/52 ,  Y02A50/484

摘要： The present invention relates to Salmonella typhi Ty21a a comprising core-linked Shigella dysenteriae type 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2; b) DNA encoding S. dysenteriae serotype 1 biosynthesis polypeptides encoded by any one of SEQ ID NOs: 1 and 2; c) DNA encoding variants of the polypeptide encoded by the DNA of (a) or (b), wherein the variants comprise O antigen biosynthesis polypeptide analogs, wherein one or more of the specified amino acids is deleted or replaced, or wherein one or more non-specified amino acids are added without loss of biosynthesis of Shigella dysenteriae serotype 1 O antigen or protective immunological activity of the O antigen biosynthesis gene product; and d) nucleic acid molecules encoding gene products that share at least about 90% sequence identity with the polypeptide encoded by the nucleic acid molecule of SEQ ID NO: 1 or 2.

公开(公告)号：EP1697530A1

公开(公告)日：2006-09-06

申请号：EP04803729.5

申请日：2004-12-10

申请人： Degussa AG

发明人： DUSCH, Nicole

IPC分类号： C12P13/08 ,  C12N15/31 ,  C07K14/245 ,  C07K14/25 ,  C07K14/225

CPC分类号： C07K14/245 ,  C07K14/25 ,  C07K14/255 ,  C12P13/08

摘要： The invention relates to a process for preparing L-amino acids by fermenting recombinant microorganisms of the Enterobacteriaceae family, characterized in that a) the desired L-amino acid-producing microorganisms, in which the yaaU ORF, or nucleotide sequences or alleles encoding the gene products, is/are enhanced, in particular overexpressed, is cultured in a medium under conditions under which the desired L-amino acid is enriched in the medium or in the cells, and b) the desired L-amino acid is isolated, with, optionally, constituents of the fermentation broth, and/or the biomass remaining in its/their entirety or in portions (from = 0 to 100%) in the isolated product or being removed completely.

摘要翻译： 本发明涉及通过发酵肠杆菌科的重组微生物制备L-氨基酸的方法，其特征在于a）所需的L-氨基酸生产微生物，其中yaaU ORF或编码该基因的核苷酸序列或等位基因 产物被增强，特别是过表达，在培养基中或在细胞中富集所需L-氨基酸的条件下培养于培养基中，并且b）分离期望的L-氨基酸， 任选地，发酵培养液的成分，和/或在其分离产物中全部或部分保留（从= 0至100％）或完全去除的生物质。

公开(公告)号：EP0998493B1

公开(公告)日：2004-11-24

申请号：EP98935164.8

申请日：1998-07-17

申请人： NEUTEC PHARMA PLC

发明人： BURNIE, James Peter ,  MATTHEWS, Ruth Christine

IPC分类号： C07K14/425 ,  C07K14/25 ,  C07K16/12 ,  A61K39/108 ,  A61K39/112 ,  G01N33/68

CPC分类号： C07K14/25 ,  A61K39/00 ,  C07K14/245

摘要： The present invention concerns immunogenic epitopes of Shigella-like toxins (SLTs), particularly the Shigella-like toxin of E.coli O157:H7, their use as immunogens and in treatment or diagnosis, agents (for example antibodies and antigen-binding fragments) which specifically neutralise them, their use in treatment and diagnosis, and methods for same.